62 results
8-K
EX-99.1
ALXO
Alx Oncology Holdings Inc
28 Feb 22
Results of Operations and Financial Condition
7:46am
. The decrease in related-party revenue relates to the termination of the research and development agreement with Tallac Therapeutics, Inc. in July 2020 … .
Research and Development (“R&D”) Expenses: R&D expenses consist primarily of pre-clinical, clinical and manufacturing expenses related
8-K
EX-99.1
ALXO
Alx Oncology Holdings Inc
8 Nov 22
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:04pm
through mid-2025.
Research and Development (“R&D”) Expenses: These expenses for the three months ended September 30, 2022 were $29.4 million, compared … to $18.2 million for the prior-year period. Research and development expenses increased by $11.2 million during the three months ended September 30
10-Q
2020 Q2
ALXO
Alx Oncology Holdings Inc
27 Aug 20
Quarterly report
4:49pm
, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs …
Six Months Ended
June 30,
Related-party revenue
Operating expenses:
Research and development
General and administrative
Cost of services for related
DRS/A
EX-10.14
prjv 3f7qfo5cz
12 Jun 20
Draft registration statement (amended)
12:00am
S-1
EX-10.14
fl8wpz
26 Jun 20
IPO registration
4:34pm
8-K
EX-99.1
nr3 ni2bebrblyjk
13 Nov 23
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
10-K
lrabt6
18 Mar 21
Annual report
4:25pm
8-K
EX-99.1
lzta75payti6
17 May 21
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
4:10pm
8-K
EX-99.1
1tupgi
9 May 22
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
4:04pm
8-K
EX-99.1
wv3zdn jh5
7 Mar 24
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:05pm